SPL-108

News alerts, weekly reports and conference planners

Company:

Splash Pharma

Drug class:

CD44 modulator

‹

›

over1year

SPL-108 mitigates metastasis and chemoresistance in tubo-ovarian carcinoma. (PubMed, Transl Oncol)

SPL-108 treatment has anti-metastatic properties and may play a role in chemoresistance in preclinical models of TOCs independent of CD44 expression. Ongoing in vitro and in vivo studies will help guide further clinical development of SPL-108.

over 1 year ago

Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CD44 (CD44 Molecule)

CD44 expression

SPL-108

over3years

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. (PubMed, Int J Gynecol Cancer)

The combination of SPL-108 with weekly paclitaxel was safe and well tolerated. Encouraging antitumor activity was observed, with 72% of patients deriving a clinical benefit.

over 3 years ago

P1 data • Journal • Combination therapy

CD44 (CD44 Molecule)

CD44 expression

paclitaxel • SPL-108

4years

PARP and ABCB1 (MDR1) inhibitor treatment of ovarian cancer cell lines and PDX models demonstrate no synergistic effect (SGO 2022)

Learning Objective: Discuss the relationship between novel therapeutic agent SPL-108 in the context of parp inhibitor resistance

4 years ago

Preclinical

ABCB1 (ATP Binding Cassette Subfamily B Member 1)

SPL-108

almost6years

[VIRTUAL] Open label phase I trial using SPL-108 in combination with weekly paclitaxel final report with molecular correlates. (ASCO 2020)

Daily SPL-108 300mg SQ in combination with weekly PTX is safe and feasible. The promising clinical activity on drug resistant ovarian tumors warrants further investigation. Resistance to SPL-108 are characterized by lack of function of TP53, mostly early truncations.

almost 6 years ago

Clinical • P1 data • Combination therapy

TP53 (Tumor protein P53) • CD44 (CD44 Molecule)

paclitaxel • SPL-108